Jason Zemansky, an analyst from Bank of America Securities, maintained the Buy rating on Insmed (INSM – Research Report). The associated price target remains the same with $96.00.
Jason Zemansky has given his Buy rating due to a combination of factors, primarily centered around Insmed’s promising pipeline and market potential. The company has shown a strong start to the year, with significant investor interest in brensocatib for lung disease, and there is anticipation for further growth as updates on their pipeline, including the treprostinil pro-drug (TPIP), are expected.
Moreover, key opinion leaders are optimistic about TPIP’s potential to differentiate itself in the pulmonary arterial hypertension market by exceeding efficacy thresholds, particularly in terms of pulmonary vascular resistance reduction. Additionally, TPIP’s safety profile and once-daily dosing could provide a competitive edge over existing treatments. Despite concerns about new competitors like Merck’s sotatercept, TPIP’s improved tolerability positions it well as a potential combination therapy, which could capture a significant share of the market, supporting Zemansky’s Buy rating.
Zemansky covers the Healthcare sector, focusing on stocks such as Insmed, Madrigal Pharmaceuticals, and Esperion. According to TipRanks, Zemansky has an average return of 2.7% and a 43.61% success rate on recommended stocks.
In another report released on March 24, Wells Fargo also maintained a Buy rating on the stock with a $107.00 price target.